Dr. Masters writes: “…with the advent of coronavirus vaccines, dropping case and mortality rates, and at least some calming of recent societal tensions, it feels as though there may at last
Seven-day quarantine may be sufficient for contacts without symptoms, older adults with mild disease may benefit from convalescent plasma, and cardiovascular deaths increased during the early stage of the pandemic.
Patients with SARS-CoV-2 who received twice-daily, automated text message check-ins with an option to report worsening symptoms at any time had lower 30- and 60-day mortality than outpatients receiving usual care, a retrospective study found.
Researchers published evidence of re-infection with SARS-CoV-2, anticoagulation was associated with halved inpatient mortality, recommendations were made on pulmonary embolism in COVID-19, and a study attributed differences in men's and women's
An accompanying editorial noted that obesity is a common but difficult-to-change risk factor, so measures to avoid coronavirus infection should be recommended to at-risk patients.
The FDA and CDC endorsed boosters of the Johnson & Johnson and Moderna vaccines. Recent research showed that COVID-19 vaccination was not associated with miscarriage, and a small financial incentive for receiving a COVID-19 vaccine or providing
A peer-reviewed study showed molnupiravir reduced hospitalizations and deaths in high-risk patients, the CDC favored mRNA vaccines over J&J's, experts explained potential issues with waning efficacy data, and a study quantified the low risk of
More cases of the novel coronavirus disease (COVID-19) are being reported around the world, including in the U.S., and ACP and the CDC have both developed updated information for
The U.S. tool (the CDC Coronavirus Symptom Checker) triaged 38% of cases to health care contact and consistently failed to identify severe COVID-19 or bacterial pneumonia and sepsis, triaging
Two Israeli studies showed that vaccine boosters reduced rates of infection and severe disease. Experts gathered for the seventh ACP and Annals of Internal Medicine virtual forum on COVID-19. The FDA authorized a monoclonal antibody for pre-exposure